These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 23088517

  • 1. Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner.
    Li Q, Hu Y, Xi M, He L, Zhao L, Liu M.
    BMC Cancer; 2012 Oct 22; 12():485. PubMed ID: 23088517
    [Abstract] [Full Text] [Related]

  • 2. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF, Ding J, Zhang RG, Ren JH, Ma CM, Wu G.
    Int J Radiat Biol; 2013 Sep 22; 89(9):724-31. PubMed ID: 23682582
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo.
    Yu W, Gu K, Yu Z, Yuan D, He M, Ma N, Lai S, Zhao J, Ren Z, Zhang X, Shao C, Jiang GL.
    Cancer Lett; 2013 Feb 01; 329(1):109-17. PubMed ID: 23142289
    [Abstract] [Full Text] [Related]

  • 4. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.
    Wild AT, Gandhi N, Chettiar ST, Aziz K, Gajula RP, Williams RD, Kumar R, Taparra K, Zeng J, Cades JA, Velarde E, Menon S, Geschwind JF, Cosgrove D, Pawlik TM, Maitra A, Wong J, Hales RK, Torbenson MS, Herman JM, Tran PT.
    PLoS One; 2013 Feb 01; 8(6):e65726. PubMed ID: 23762417
    [Abstract] [Full Text] [Related]

  • 5. [Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402].
    Li N, Zhang Y, Wu T, Li M.
    Ai Zheng; 2009 Aug 01; 28(8):838-43. PubMed ID: 19664330
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells.
    Möckelmann N, Rieckmann T, Busch CJ, Becker B, Gleißner L, Hoffer K, Omniczynski M, Steinmeister L, Laban S, Grénman R, Petersen C, Rothkamm K, Dikomey E, Knecht R, Kriegs M.
    Oncotarget; 2016 Apr 26; 7(17):23542-51. PubMed ID: 27015558
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib acts synergistically in combination with radiotherapy without causing intestinal damage in colorectal cancer.
    Jeong YK, Kim MS, Lee JY, Kim EH, Kim W, Ha H, Jeong JH.
    Tumori; 2013 Apr 26; 99(2):176-82. PubMed ID: 23748811
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.
    Zhou S, Ye W, Duan X, Zhang M, Wang J.
    Dig Dis Sci; 2013 Jun 26; 58(6):1615-26. PubMed ID: 23314856
    [Abstract] [Full Text] [Related]

  • 11. Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
    Deng L, Ren Z, Jia Q, Wu W, Shen H, Wang Y.
    BMC Cancer; 2013 Jul 29; 13():363. PubMed ID: 23895220
    [Abstract] [Full Text] [Related]

  • 12. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
    Gu HR, Park SC, Choi SJ, Lee JC, Kim YC, Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, No SH, Jeong JH.
    Clin Mol Hepatol; 2015 Mar 29; 21(1):49-59. PubMed ID: 25834802
    [Abstract] [Full Text] [Related]

  • 13. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY, Tai WT, Hsieh CY, Hsu WM, Lai YJ, Chen LJ, Shiau CW, Chen KF.
    Cancer Lett; 2014 Jul 28; 349(2):136-43. PubMed ID: 24735751
    [Abstract] [Full Text] [Related]

  • 14. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 28; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer.
    Kim YB, Jeung HC, Jeong I, Lee K, Rha SY, Chung HC, Kim GE.
    J Radiat Res; 2013 Jan 28; 54(1):52-60. PubMed ID: 22923745
    [Abstract] [Full Text] [Related]

  • 16. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z, Wu J, Wu J, Luo D, Jiang C, Ding Y.
    J Exp Clin Cancer Res; 2016 Sep 30; 35(1):159. PubMed ID: 27716356
    [Abstract] [Full Text] [Related]

  • 17. Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition.
    Yang Y, Qin SK, Wu Q, Wang ZS, Zheng RS, Tong XH, Liu H, Tao L, He XD.
    Oncol Rep; 2014 Feb 30; 31(2):540-50. PubMed ID: 24317203
    [Abstract] [Full Text] [Related]

  • 18. Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.
    Huang CY, Lin CS, Tai WT, Hsieh CY, Shiau CW, Cheng AL, Chen KF.
    Int J Radiat Oncol Biol Phys; 2013 Jul 01; 86(3):456-62. PubMed ID: 23474115
    [Abstract] [Full Text] [Related]

  • 19. Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma.
    Jeong KY, Lee EJ, Yang SH, Seong J.
    J Radiat Res; 2015 Jan 01; 56(1):37-45. PubMed ID: 25225286
    [Abstract] [Full Text] [Related]

  • 20. Radiosensitization by the novel DNA intercalating agent vosaroxin.
    Gordon IK, Graves C, Kil WJ, Kramp T, Tofilon P, Camphausen K.
    Radiat Oncol; 2012 Feb 27; 7():26. PubMed ID: 22369205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.